Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Metabolic dysfunction-associated steatotic liver disease (MASLD): look for advanced fibrosis

Gastroenterology and hepatology · Known disease · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: About 25% of the general population [1]

Steatosis or at-risk patient: initial tests

Fasting sample.

Fasting laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Do not order

FIB-4: interpret and act

Second step, if FIB-4 ≥ 1.30 (≥ 2.0 after age 65)

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Follow-up of steatosis without advanced fibrosis

Fasting sample.

Every 1 to 3 years (see the note)

Every year in prediabetes

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Sources (7)
  1. Association française pour l'étude du foie (AFEF). Recommandations pour le diagnostic et le suivi non-invasif des maladies chroniques du foie (coord. V. de Lédinghen). Juillet 2020. Chapitre 4 : stéatopathie métabolique (J. Boursier).
  2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542 (PMID 38851997) ; co-publié dans Obes Facts. 2024;17(4):374-444.
  3. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
  4. National Institute for Health and Care Excellence (NICE). Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management. NICE guideline NG49, publiée le 6 juillet 2016, dernière mise à jour le 31 juillet 2026 (recommandations 1.1 à 1.3).
  5. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1000 à 1002 (scores biologiques de fibrose hépatique) ; absence d'acte pour le test ELF.
  6. Ohri S, Waterman E, Quiñones AR. Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management. Am Fam Physician. 2026;113(6):578-585.
  7. Akuta N, Kogiso T, Ikejima K, Otsuka M, Kawaguchi T, Kawanaka M, et al. Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026 (Japanese Society of Gastroenterology, Japan Society of Hepatology). J Gastroenterol. 2026;61(6):693-710.